• Nine companies plan to price IPOs on U.S. exchanges this week: Change Healthcare, TheRealReal, Linx, BridgeBio Pharma, Adaptive Biotech, Cambium Networks, Morphic Holding, Priam Properties and Karuna Therapeutics. http://axios.link/9PAm
• ConversionPoint, a Newport Beach, Calif.-based SaaS platform for marketing and e-commerce, formally withdrew its $40 million IPO registration. It had postponed the offering last month.
🚑 Fulcrum Therapeutics, a Cambridge, Mass.-based developer of rare disease therapies based on gene regulation, filed for an $86 million IPO. The pre-revenue company plans to trade on the Nasdaq (FULC) with Morgan Stanley as lead underwriter, and raised around $140 million from Third Rock Ventures (43.2% pre-IPO stake), GlaxoSmithKline (9.5%) and Foresite Capital (8%). http://axios.link/hc3Y
• Medallia, a San Francisco-based customer experience feedback platform, filed for a $100 million IPO. It plans to trade on the NYSE (MDLA) with BAML as lead underwriter. It reports a $2.6 million net loss on $94 million in revenue for Q1 2019, and raised over $330 million from firms like Sequoia Capital (41% pre-IPO stake). http://axios.link/PHF6
🚑 Mirum Pharma, a Foster City, Calif.-based developer of treatments for cholestatic liver diseases, filed for an $86 million IPO. The pre-revenue company plans to trade on the Nasdaq (MIRM) with Citigroup as lead underwriter, and raised $120 million from NEA (20.8% pre-IPO stake), Deerfield Management (17.3%), Frazier Life Sciences (17.3%), Novo (10.4%), Shire (10.3%) and RiverVest (9%). http://axios.link/I9V5
🚑 Phressia, a New York-based provider of patient-intake software, filed for a $125 million IPO. It plans to trade on the NYSE (PHR) with JPMorgan as lead underwriter, and reports a $7 million net loss on $28 million in revenue for Q1 2019. The company raised around $119 million in VC funding from LLR Equity (23.85% pre-IPO stake), HLM Venture Partners (17.33%), Polaris Partners (14.52%), Ascension Ventures (10.77%), Echo Health Venture (9.01%), Blue Cross Blue Shield Venture Partners (7.8%) and VantagePoint Venture Partners (7.08%). http://axios.link/8hu7